异基因造血干细胞移植治疗54例骨髓增生异常综合征转化急性髓系白血病的疗效和预后分析

目的:评估异基因造血干细胞移植(allo-HSCT)治疗骨髓增生异常综合征转化急性髓系白血病(MDS-AML)的疗效。方法:收集2018年1月至2022年8月在中国医学科学院血液病医院接受allo-HSCT的MDS-AML患者,对其临床资料进行回顾性分析。结果:54例患者纳入研究,男26例,女28例,中位年龄46(9~57)岁。53例患者获得粒系造血重建。中位随访597(15~1 934)d。移植后1年总生存(OS)率、无病生存(DFS)率分别为(75.8±5.8)%、(72.1±6.1)%,累积复发率(CIR)为(12.7±4.9)%,非复发死亡率(NRM)为(17.1±5.2)%;移植后3...

Full description

Saved in:
Bibliographic Details
Published in中华血液学杂志 Vol. 45; no. 4; pp. 364 - 369
Main Authors 陈书连, 施圆圆, 张利宁, 龚明, 张潇予, 赵小利, 郝梦泽, 魏嘉璘, 何祎, 冯四洲, 韩明哲, 姜尔烈
Format Journal Article
LanguageChinese
Published 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020%天津医学健康研究院,天津 301600 14.04.2024
Subjects
Online AccessGet full text
ISSN0253-2727
DOI10.3760/cma.j.cn121090-20231101-00243

Cover

Abstract 目的:评估异基因造血干细胞移植(allo-HSCT)治疗骨髓增生异常综合征转化急性髓系白血病(MDS-AML)的疗效。方法:收集2018年1月至2022年8月在中国医学科学院血液病医院接受allo-HSCT的MDS-AML患者,对其临床资料进行回顾性分析。结果:54例患者纳入研究,男26例,女28例,中位年龄46(9~57)岁。53例患者获得粒系造血重建。中位随访597(15~1 934)d。移植后1年总生存(OS)率、无病生存(DFS)率分别为(75.8±5.8)%、(72.1±6.1)%,累积复发率(CIR)为(12.7±4.9)%,非复发死亡率(NRM)为(17.1±5.2)%;移植后3年OS率、DFS率分别为(57.8±7.5)%、(58.1±7.2)%,CIR为(23.2±6.6)%,NRM为(23.7±6.6)%。急性移植物抗宿主病(aGVHD)累积发生率为(57.5±6.9)%,慢性移植物抗宿主病(cGVHD)累积发生率为(48.4±7.7)%。单因素分析显示,移植前造血干细胞移植合并症指数(HCT-CI)评分≥2分、造血植入时骨髓微小残留病(MRD)阳性、发生Ⅲ/Ⅳ度aGVHD、发生细菌/真菌感染以及未发生cGVHD是影响OS的不良因素( P<0.05)。多因素因素分析显示,HCT-CI评分≥2分( P=0.001, HR=6.981,95% CI 2.186~22.300)、造血植入时骨髓MRD阳性( P=0.010, HR=6.719,95% CI 572~28.711)、发生Ⅲ/Ⅳ度aGVHD( P=0.026, HR=3.386,95% CI 1.158~9.901)以及cGVHD( P=0.006, HR=0.151,95% CI 0.039~0.581)是影响OS的独立危险因素。 结论:对于高复发风险的MDS-AML患者,可考虑早期进行allo-HSCT,移植后加强并发症的处理以及在患者病情允许下尽早开始维持治疗。
AbstractList 目的:评估异基因造血干细胞移植(allo-HSCT)治疗骨髓增生异常综合征转化急性髓系白血病(MDS-AML)的疗效。方法:收集2018年1月至2022年8月在中国医学科学院血液病医院接受allo-HSCT的MDS-AML患者,对其临床资料进行回顾性分析。结果:54例患者纳入研究,男26例,女28例,中位年龄46(9~57)岁。53例患者获得粒系造血重建。中位随访597(15~1 934)d。移植后1年总生存(OS)率、无病生存(DFS)率分别为(75.8±5.8)%、(72.1±6.1)%,累积复发率(CIR)为(12.7±4.9)%,非复发死亡率(NRM)为(17.1±5.2)%;移植后3年OS率、DFS率分别为(57.8±7.5)%、(58.1±7.2)%,CIR为(23.2±6.6)%,NRM为(23.7±6.6)%。急性移植物抗宿主病(aGVHD)累积发生率为(57.5±6.9)%,慢性移植物抗宿主病(cGVHD)累积发生率为(48.4±7.7)%。单因素分析显示,移植前造血干细胞移植合并症指数(HCT-CI)评分≥2分、造血植入时骨髓微小残留病(MRD)阳性、发生Ⅲ/Ⅳ度aGVHD、发生细菌/真菌感染以及未发生cGVHD是影响OS的不良因素( P<0.05)。多因素因素分析显示,HCT-CI评分≥2分( P=0.001, HR=6.981,95% CI 2.186~22.300)、造血植入时骨髓MRD阳性( P=0.010, HR=6.719,95% CI 572~28.711)、发生Ⅲ/Ⅳ度aGVHD( P=0.026, HR=3.386,95% CI 1.158~9.901)以及cGVHD( P=0.006, HR=0.151,95% CI 0.039~0.581)是影响OS的独立危险因素。 结论:对于高复发风险的MDS-AML患者,可考虑早期进行allo-HSCT,移植后加强并发症的处理以及在患者病情允许下尽早开始维持治疗。
Abstract_FL Objective:The outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndromes-evolved acute myeloid leukemia (MDS-AML) were explored.Methods:A retrospective review was conducted for 54 patients with MDS-AML treated with allo-HSCT in the Institute of Hematology and Blood Disease Hospital from January 2018 to August 2022. The clinical effects after transplantation were observed, and the related risk factors influencing prognosis were explored.Results:Of the total 54 patients, 26 males, 28 females, and 53 patients achieved hematopoietic reconstruction. After a median follow-up of 597 (15-1 934) days, the 1 year overall survival (OS) rate, disease-free survival (DFS) rate, relapse rate (CIR) and non-relapse mortality (NRM) rate were 75.8%±5.8%, 72.1%±6.1%, 12.7%±4.9%, and 17.1%±5.2%, respectively. The 3 year estimated OS, DFS, CIR, and NRM rates were 57.8%±7.5%, 58.1%±7.2%, 23.2%±6.6%, and 23.7%±6.6%, respectively. The cumulative incidence of acute graft-versus-host disease (aGVHD) was 57.5%±6.9%, and the cumulative incidence of chronic graft-versus-host disease (cGVHD) was 48.4%±7.7%. Hematopoietic cell transplantation comorbidity index (HCT-CI) before transplantation was ≥2, minimal residual disease (MRD) was positive on the day of reconstitution, grade Ⅲ/Ⅳ aGVHD, bacterial or fungal infection and no cGVHD after transplantation were adverse prognostic factors for OS ( P<0.05). COX regression model for multivariate analysis showed that HCT-CI score before transplantation, bone marrow MRD on the day of response, grade Ⅲ or Ⅳ aGVHD, and cGVHD after transplantation were the independent adverse factors for OS ( P=0.001, HR=6.981, 95% CI 2.186-22.300; P=0.010, HR=6.719, 95% CI 1.572-28.711; P=0.026, HR=3.386, 95% CI 1.158-9.901; P=0.006, HR=0.151, 95% CI 0.039-0.581) . Conclusion:For patients with MDS-AML and high risk of relapse, allogeneic transplantation must be considered as soon as possible. The enhanced management of post-transplantation complications and maintenance treatment should be provided whenever possible after transplantation.
Author 赵小利
张潇予
何祎
施圆圆
张利宁
龚明
郝梦泽
冯四洲
韩明哲
姜尔烈
陈书连
魏嘉璘
AuthorAffiliation 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020%天津医学健康研究院,天津 301600
AuthorAffiliation_xml – name: 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020%天津医学健康研究院,天津 301600
Author_FL Wei Jialin
Zhang Lining
Gong Ming
Hao Mengze
Shi Yuanyuan
Zhao Xiaoli
Chen Shulian
He Yi
Zhang Xiaoyu
Han Mingzhe
Feng Sizhou
Jiang Erlie
Author_FL_xml – sequence: 1
  fullname: Chen Shulian
– sequence: 2
  fullname: Shi Yuanyuan
– sequence: 3
  fullname: Zhang Lining
– sequence: 4
  fullname: Gong Ming
– sequence: 5
  fullname: Zhang Xiaoyu
– sequence: 6
  fullname: Zhao Xiaoli
– sequence: 7
  fullname: Hao Mengze
– sequence: 8
  fullname: Wei Jialin
– sequence: 9
  fullname: He Yi
– sequence: 10
  fullname: Feng Sizhou
– sequence: 11
  fullname: Han Mingzhe
– sequence: 12
  fullname: Jiang Erlie
Author_xml – sequence: 1
  fullname: 陈书连
– sequence: 2
  fullname: 施圆圆
– sequence: 3
  fullname: 张利宁
– sequence: 4
  fullname: 龚明
– sequence: 5
  fullname: 张潇予
– sequence: 6
  fullname: 赵小利
– sequence: 7
  fullname: 郝梦泽
– sequence: 8
  fullname: 魏嘉璘
– sequence: 9
  fullname: 何祎
– sequence: 10
  fullname: 冯四洲
– sequence: 11
  fullname: 韩明哲
– sequence: 12
  fullname: 姜尔烈
BookMark eNotkEtLAlEcxe_CIK0-Ru3G_vfOndcypBcIbWot8yykRmgIrdVUJkIW0kOpQE0Ko1rZxhr103TnOt-iiVqdzTm_czgplHALro3QPIa0qMiwaO7p6XzadDHBoIFAgIgYAxYACBUTKAlEEgWiEGUapTwvD0AJYJpERTY8Ye0v9tCJ_M7k0WeffR5UJqct3gvCp4uwH_BGU6Lf4_Po9SV6u2bdFr9p_4YGAx4MWb3KxseT0TurNUL_OfR7sYd_BPxuFMN484zfl2NAeFtlV7WoW2b1S1athK36LJpy9F3PnvvXGbS1sryZWROyG6vrmaWs4MXrVUGnmm5KDhaVeK4BJqXggG1ZqiGbRFING4gmG9hyHANjmVpYdjRb0nSwNFW2wBJn0MIft6i7ju5u5_KFg303bswd7ZQOS_FPFCiAKv4AQxyLsQ
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3760/cma.j.cn121090-20231101-00243
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia
EndPage 369
ExternalDocumentID zhxyx202404008
GroupedDBID ---
-05
2B.
4A8
92F
92I
93N
ABJNI
ACGFS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CW9
F5P
OK1
PSX
RPM
TCJ
TGQ
U1G
U5O
ID FETCH-LOGICAL-s1018-a49ac5f137201b0c440f0edd8b6c258be0296b1dffb1164d16f9e59a0d986d0d3
ISSN 0253-2727
IngestDate Thu May 29 04:09:54 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords Leukemia transformation
白血病转化
造血干细胞移植
Myelodysplastic syndromes
Hematopoietic stem cell transplantation
骨髓增生异常综合征
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1018-a49ac5f137201b0c440f0edd8b6c258be0296b1dffb1164d16f9e59a0d986d0d3
PageCount 6
ParticipantIDs wanfang_journals_zhxyx202404008
PublicationCentury 2000
PublicationDate 2024-04-14
PublicationDateYYYYMMDD 2024-04-14
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-14
  day: 14
PublicationDecade 2020
PublicationTitle 中华血液学杂志
PublicationTitle_FL Chinese Journal of Hematology
PublicationYear 2024
Publisher 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020%天津医学健康研究院,天津 301600
Publisher_xml – name: 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020%天津医学健康研究院,天津 301600
SSID ssj0042014
ssib051368330
ssib001103535
ssib058574913
Score 2.4128458
Snippet 目的:评估异基因造血干细胞移植(allo-HSCT)治疗骨髓增生异常综合征转化急性髓系白血病(MDS-AML)的疗效。方法:收集2018年1月至2022年8月在中国医学科学院血液病医院接...
SourceID wanfang
SourceType Aggregation Database
StartPage 364
Title 异基因造血干细胞移植治疗54例骨髓增生异常综合征转化急性髓系白血病的疗效和预后分析
URI https://d.wanfangdata.com.cn/periodical/zhxyx202404008
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQN
  databaseName: PubMed Central
  issn: 0253-2727
  databaseCode: RPM
  dateStart: 20150101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  omitProxy: true
  ssIdentifier: ssj0042014
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9RGFLa4VKgvVasWQa88MI8bPLZnPPPo2XWEKpUnkPIW-bIGIbFIEETIU6AURSqtol5AbaVwESgV9Cl9oV0S8WPwOvkXnHPstU2yQEBCWllnZ47P-c5lPBeNx5Z11E2TSERZvwOx7XcgQ6JOrCTvZDxzdZwI4dABpt-dkMdPed_OiJk9Hzxr7Vq6NBdPJQsT3yt5l6hCGcQV35J9i8jWQqEAaIgvXCHCcN1VjFkomOky5SChp5kJiDAssFmocRMDEooFHGlk1swAs8-MYUpilXKZDrEkoMJQsgBGlz0kgBNLfKYl077wWOgxEzJlUHYQsEARYZh2UXbgVJK0h1ja0IzCX6kWChGjzZSiKhDIEYjpsYCqVBcVgn6EL8aE39IFctwxNI03NiZCic-UICJgyqvhoxwtKqXaQS0o0CGeEk9I2hU5RqIt5RdGx0N3Mh8U9YitR_y1XvAWOQz9AIaUEnpj86eZrrt7VAuoEYiH8QgoDMgSNiwSQRvSpLsEqCIaFnJvYFeYA02q0ZltReBdcAOKA7PC9gqPQxuDeLPC-5J5kEKldnATOrq2ivJE81YJWQN-nOCLOhi1nJp5mpJDvQel7btszEUkNNZiJlGjqLTrMdGdJIeAVTnBKREFti_jU4mg7K8xg1ifWo2PITfjYGB7oKaiulUJNK5GactkqDJysg_rXIcrtitKaBO23EtQjVchVMErfLjNGy3PQ_bBc6ABNun5ULVqao3YYgGDIG-UDwp3tybDX0xWiYDRqy4JhEEATimZIybx7DRnZ1B2Grgt2V6vnUvbbg2KoO_oOH55nsh4BFceSFv1VF5rOOaWX0ioRvZu-VGo7YNG3BYIT_rkXDR1dioZ4ImK2oZ-Bma-HNda8czWZrRc72FeODN_ZR6bKw6D1F5rv-NL6WxbLwYJrmgmpIK7UrnNgo1Qwvdon0g5d_BgOkYHHo6tPGCxCuGx1-KjV04HWTQ43ZodnfzY-qha1jgSlH3UJ9aehTOfWpfzp9fyO__nf93dWry7eW8x_2-tGN7Y_H6lWB2OHvw0WhsWt24L7_nGj1uP_t56_Gt-f6X47Q7e9ORJMXyaLy_lG1c31__Jb94aLT4cLa4CT_HvsPhjHYQVt38o_rwOAka_L-W_3Ny6fz1f_jlfujFaWf7MOjUdnuwe71Qf-ulcxAMjO5Gno0RkHL-YxmM78Tw7s_tpqmKZOELFfdvRMuZplsWcSy_lMtN9oSM71UqmduoetPYNzg_6h6wjUji-1n7qwuTPy2SkNM8SmNYqqEhEwg9b31SOmq068ouzL0fy8zdyfGF92Dymv7T2zV241P8KpqZz8dcU_RdC9F-T
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%BC%82%E5%9F%BA%E5%9B%A0%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E6%B2%BB%E7%96%9754%E4%BE%8B%E9%AA%A8%E9%AB%93%E5%A2%9E%E7%94%9F%E5%BC%82%E5%B8%B8%E7%BB%BC%E5%90%88%E5%BE%81%E8%BD%AC%E5%8C%96%E6%80%A5%E6%80%A7%E9%AB%93%E7%B3%BB%E7%99%BD%E8%A1%80%E7%97%85%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E9%A2%84%E5%90%8E%E5%88%86%E6%9E%90&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E9%99%88%E4%B9%A6%E8%BF%9E&rft.au=%E6%96%BD%E5%9C%86%E5%9C%86&rft.au=%E5%BC%A0%E5%88%A9%E5%AE%81&rft.au=%E9%BE%9A%E6%98%8E&rft.date=2024-04-14&rft.pub=%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E8%A1%80%E6%B6%B2%E7%97%85%E5%8C%BB%E9%99%A2%EF%BC%88%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E8%A1%80%E6%B6%B2%E5%AD%A6%E7%A0%94%E7%A9%B6%E6%89%80%EF%BC%89%EF%BC%8C%E8%A1%80%E6%B6%B2%E4%B8%8E%E5%81%A5%E5%BA%B7%E5%85%A8%E5%9B%BD%E9%87%8D%E7%82%B9%E5%AE%9E%E9%AA%8C%E5%AE%A4%EF%BC%8C%E5%9B%BD%E5%AE%B6%E8%A1%80%E6%B6%B2%E7%B3%BB%E7%BB%9F%E7%96%BE%E7%97%85%E4%B8%B4%E5%BA%8A%E5%8C%BB%E5%AD%A6%E7%A0%94%E7%A9%B6%E4%B8%AD%E5%BF%83%EF%BC%8C%E7%BB%86%E8%83%9E%E7%94%9F%E6%80%81%E6%B5%B7%E6%B2%B3%E5%AE%9E%E9%AA%8C%E5%AE%A4%EF%BC%8C%E5%A4%A9%E6%B4%A5%E3%80%80300020%25%E5%A4%A9%E6%B4%A5%E5%8C%BB%E5%AD%A6%E5%81%A5%E5%BA%B7%E7%A0%94%E7%A9%B6%E9%99%A2%EF%BC%8C%E5%A4%A9%E6%B4%A5%E3%80%80301600&rft.issn=0253-2727&rft.volume=45&rft.issue=4&rft.spage=364&rft.epage=369&rft_id=info:doi/10.3760%2Fcma.j.cn121090-20231101-00243&rft.externalDocID=zhxyx202404008
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg